Literature DB >> 30013645

Follow-up study of HPV58 variants in women with incident HPV58 infection from a Colombian cohort.

Mónica Molano1,2,3, Oscar Buitrago1, Pablo Moreno-Acosta1,2, Suzanne M Garland3,4,5, Nicolás Morales1, Antonio Huertas1, Teresa Martinez6, Oscar Gamboa7, Sepehr N Tabrizi3,4,5, Alyssa Cornall4, Nubia Muñoz8.   

Abstract

Certain variants of human papillomavirus (HPV)type 58 are associated with an increased risk of high grade squamous intraepithelial lesions and cervical cancer. However, little is known about the persistence of HPV58 E6/E7 variants in women with incident HPV58 infections. The aim of the present study was to evaluate the presence and persistence of HPV58 E6/E7 variants in 71 women with incident HPV58 infection throughout their follow-up. These women belonged to a cohort examined in a longitudinal study of 1,610 Colombian women, who were HPV-negative and had normal baseline cytology. E6/E7 DNA regions of HPV58-positive samples were amplified and sequenced using automated direct sequencing. A total of 639 samples were analyzed from the 71 women, and 117 samples (18.3%) were HPV58-positive. HPV58 E6/E7 variants were detected in 85.5% of the samples. The T307/A694/G744/A761 variant was identified in 88% of the samples, the T307/G744 variant was identified in 9% of samples and the T187/T307/A367/G744/G793/T798/A801/T840/C852 was identified in 3% of the samples. Overall, 50% of the HPV58 infections were present after 1 year of follow-up and all infections were cleared after 7 years. Women who had first sexual intercourse at >15 years of age had a lower clearance rate than those who had sexual intercourse for the first time at ≤15 years of age [hazard ratio (HR)=0.29; 95% confidence interval (CI)=0.09-0.92]. Likewise, parous women had a higher clearance rate than nulliparous women (HR=3.43, 95% CI=1.23-9.60). There was no difference in clearance rates between HPV58 E6/E7 variants. In conclusion, HPV58 variants were not associated with persistence of the infection in this group of women.

Entities:  

Keywords:  follow-up studies; genomic variation; human papilloma virus; persistent infection

Year:  2018        PMID: 30013645      PMCID: PMC6036590          DOI: 10.3892/ol.2018.8928

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  34 in total

1.  Cervical coinfection with human papillomavirus (HPV) types and possible implications for the prevention of cervical cancer by HPV vaccines.

Authors:  Fabian Mendez; Nubia Munoz; Hector Posso; Monica Molano; Victor Moreno; Adrian J C van den Brule; Margarita Ronderos; Chris Meijer; Alvaro Munoz
Journal:  J Infect Dis       Date:  2005-08-29       Impact factor: 5.226

2.  High prevalence and low E6 genetic variability of human papillomavirus 58 in women with cervical cancer and precursor lesions in Southeast Mexico.

Authors:  Jaqueline Canul Canche; Iván Rosado López; Nicolás G Suárez; Gladis Colli Acosta; Laura Conde-Ferráez; Thelma Canto de Cetina; María R González Losa
Journal:  Mem Inst Oswaldo Cruz       Date:  2010-03       Impact factor: 2.743

3.  Incidence, duration, and determinants of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological results.

Authors:  Nubia Muñoz; Fabián Méndez; Héctor Posso; Mónica Molano; Adrian J C van den Brule; Margarita Ronderos; Chris Meijer; Alvaro Muñoz
Journal:  J Infect Dis       Date:  2004-11-22       Impact factor: 5.226

4.  Worldwide genomic diversity of the high-risk human papillomavirus types 31, 35, 52, and 58, four close relatives of human papillomavirus type 16.

Authors:  Itzel E Calleja-Macias; Luisa L Villa; Jose C Prado; Mina Kalantari; Bruce Allan; Anna-Lise Williamson; Lap-Ping Chung; Robert J Collins; Rosemary E Zuna; S Terence Dunn; Tang-Yuan Chu; Heather A Cubie; Kate Cuschieri; Magnus von Knebel-Doeberitz; Claudia R Martins; Gloria I Sanchez; F Xavier Bosch; Nubia Munoz; Hans-Ulrich Bernard
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

5.  Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study.

Authors:  Silvia de Sanjose; Wim Gv Quint; Laia Alemany; Daan T Geraets; Jo Ellen Klaustermeier; Belen Lloveras; Sara Tous; Ana Felix; Luis Eduardo Bravo; Hai-Rim Shin; Carlos S Vallejos; Patricia Alonso de Ruiz; Marcus Aurelho Lima; Nuria Guimera; Omar Clavero; Maria Alejo; Antonio Llombart-Bosch; Chou Cheng-Yang; Silvio Alejandro Tatti; Elena Kasamatsu; Ermina Iljazovic; Michael Odida; Rodrigo Prado; Muhieddine Seoud; Magdalena Grce; Alp Usubutun; Asha Jain; Gustavo Adolfo Hernandez Suarez; Luis Estuardo Lombardi; Aekunbiola Banjo; Clara Menéndez; Efrén Javier Domingo; Julio Velasco; Ashrafun Nessa; Saibua C Bunnag Chichareon; You Lin Qiao; Enrique Lerma; Suzanne M Garland; Toshiyuki Sasagawa; Annabelle Ferrera; Doudja Hammouda; Luciano Mariani; Adela Pelayo; Ivo Steiner; Esther Oliva; Chris Jlm Meijer; Waleed Fahad Al-Jassar; Eugenia Cruz; Thomas C Wright; Ana Puras; Cecilia Ladines Llave; Maria Tzardi; Theodoros Agorastos; Victoria Garcia-Barriola; Christine Clavel; Jaume Ordi; Miguel Andújar; Xavier Castellsagué; Gloria I Sánchez; Andrzej Marcin Nowakowski; Jacob Bornstein; Nubia Muñoz; F Xavier Bosch
Journal:  Lancet Oncol       Date:  2010-10-15       Impact factor: 41.316

6.  Variant-specific persistence of infections with human papillomavirus Types 31, 33, 45, 56 and 58 and risk of cervical intraepithelial neoplasia.

Authors:  Long Fu Xi; Mark Schiffman; Laura A Koutsky; James P Hughes; Ayaka Hulbert; Zhenping Shen; Denise A Galloway; Nancy B Kiviat
Journal:  Int J Cancer       Date:  2016-05-14       Impact factor: 7.396

7.  Type-specific duration of human papillomavirus infection: implications for human papillomavirus screening and vaccination.

Authors:  Helen Trottier; Salaheddin Mahmud; José Carlos M Prado; Joao S Sobrinho; Maria C Costa; Thomas E Rohan; Luisa L Villa; Eduardo L Franco
Journal:  J Infect Dis       Date:  2008-05-15       Impact factor: 5.226

8.  Association of human papillomavirus type 58 variant with the risk of cervical cancer.

Authors:  Paul K S Chan; Ching-Wan Lam; Tak-Hong Cheung; William W H Li; Keith W K Lo; May Y M Chan; Jo L K Cheung; Augustine F Cheng
Journal:  J Natl Cancer Inst       Date:  2002-08-21       Impact factor: 13.506

9.  Geographical distribution and oncogenic risk association of human papillomavirus type 58 E6 and E7 sequence variations.

Authors:  Paul K S Chan; Chuqing Zhang; Jong-Sup Park; Karen K Smith-McCune; Joel M Palefsky; Lucia Giovannelli; Francois Coutlée; Samantha Hibbitts; Ryo Konno; Wannapa Settheetham-Ishida; Tang-Yuan Chu; Annabelle Ferrera; María Alejandra Picconi; Federico De Marco; Yin-Ling Woo; Tainá Raiol; Patricia Piña-Sánchez; Jeong-Hoon Bae; Martin C S Wong; Mike Z Chirenje; Tsitsi Magure; Anna-Barbara Moscicki; Alison N Fiander; Giuseppina Capra; Eun Young Ki; Yi Tan; Zigui Chen; Robert D Burk; Martin C W Chan; Tak-Hong Cheung; David Pim; Lawrence Banks
Journal:  Int J Cancer       Date:  2012-11-29       Impact factor: 7.396

10.  Prevalence and determinants of HPV infection among Colombian women with normal cytology.

Authors:  M Molano; H Posso; E Weiderpass; A J C van den Brule; M Ronderos; S Franceschi; C J L M Meijer; A Arslan; N Munoz
Journal:  Br J Cancer       Date:  2002-07-29       Impact factor: 7.640

View more
  2 in total

1.  Human Papillomavirus 58 E7 T20I/G63S Variant Isolated from an East Asian Population Possesses High Oncogenicity.

Authors:  Siaw Shi Boon; Chichao Xia; Jin Yan Lim; Zigui Chen; Priscilla T Y Law; Apple C M Yeung; Miranda Thomas; Lawrence Banks; Paul K S Chan
Journal:  J Virol       Date:  2020-03-31       Impact factor: 5.103

2.  Genetic variability of E6 and E7 genes of human papillomavirus type 58 in Jingzhou, Hubei Province of central China.

Authors:  Zhiping Yang; Chunlin Zhang; Ping Luo; Mengxia Ye; Quan Gong; Bing Mei
Journal:  Virol J       Date:  2022-04-22       Impact factor: 4.099

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.